Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
KB407 and KB408 are modified, replication-defective, non-integrating HSV-1 vectors formulated for inhaled delivery to the lung via nebulization. KB407 encodes two full-length copies of cystic fibrosis transmembrane conductance regulator (CFTR) and is under investigation for the treatment of cystic fibrosis irrespective of underlying patient mutation. KB408 encodes two full-length copies of alpha-1 antitrypsin and is under investigation for the treatment of alpha-1 antitrypsin deficiency (AATD).
Both KB407 and KB408 are being evaluated in ongoing Phase 1 studies.
Data presented at ATS will include new preclinical data related to KB407 transduction of fully differentiated, patient airway epithelial cell-derived apical out airway organoids and production of full-length and fully glycosylated CFTR, as well as an overview of KB408 IND-enabling studies conducted to support initiation of the ongoing Phase 1 SERPENTINE-1 study in patients with AATD.
Poster presentation details are as follows:
Title: Murine Toxicology Study of Repeat-Dose Inhaled KB408, an HSV-1-Based Vector for the Treatment of Alpha-1 Antitrypsin Deficiency
Presenter:
Date and Time:
Poster Session: B70: COPD in the Spotlight: Insights into Disease Pathogenesis
Poster Number: P659
Title: Evaluation of KB407, an HSV-1-Based Gene Therapy Vector for the Treatment of Cystic Fibrosis, in Healthy and Patient-Derived Airway Cells Including an Apical-out Diseased Airway Organoid Model
Presenter:
Date and Time:
Poster Session: C70: From Buds to Breath: Mechanisms and Pathogenesis of
Poster Number: P122
The posters will be available to conference attendees. Following the presentation, the posters will also be available to view online on the Investor section of the Company’s website.
About
CONTACT
Investors and Media:
spaquette@krystalbio.com
Source: Krystal Biotech, Inc.